New Chief Scientific Officer for Caris Life Sciences

David Spetzler gains a promotion and takes responsibility for all R&D activities

Caris Life Sciences, a US biotechnology company focused on molecular profiling to fulfill the promise of precision medicine, has promoted David Spetzler to the position of Chief Scientific Officer.

Spetzler, previously Senior Vice President of Research and Development, will assume full responsibility for all research and product development activities. One of his new key priorities will be expanding the company's focus on its Carisome TOP platform, a blood-based profiling technology being studied for its utility in drug development, drug delivery, and the diagnosis, prognosis and theranosis of cancer and other complex diseases.

Spetzler has an MS from the School of Mathematical and Statistical Science in Computational Bioscience, a PhD in Molecular Cellular Biology and an MBA from Arizona State University.

Caris Life Sciences is headquartered in Irving, Texas.

You may also like

Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Subscribe now